# Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

> **NCT02868242** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 19 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** LDV/SOF

## Key facts

- **NCT ID:** NCT02868242
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-28
- **Primary completion:** 2018-11-12
- **Final completion:** 2019-02-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02868242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02868242, "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02868242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*